Article: Lev Pharmaceuticals Acquired by ViroPharma.

Article: Soligenix Announces Initiation of its Confirmatory Phase 3 ...
PR Newswire;  October 15, 2009 ;     700+ words ... ... gastrointestinal Graft-versus-Host disease (GI GVHD). The initiation of enrollment in this ... evaluating potential treatments for acute GI GVHD, only the Phase 2 and 3 studies with ... a positive impact on both controlling GI GVHD and improving patient survival. By using ...

Article: Soligenix Announces Initiation of its Confirmatory Phase 3 ...
Blood Weekly;  October 29, 2009 ;     700+ words ... ... gastrointestinal Graft-versus-Host disease (GI GVHD). The initiation of enrollment in this ... evaluating potential treatments for acute GI GVHD, only the Phase 2 and 3 studies with ... a positive impact on both controlling GI GVHD and improving patient survival. By using ...

Article: DOR BioPharma Receives EMEA Agreement on the Design of its ...
PR Newswire;  June 9, 2009 ;     700+ words ... ... gastrointestinal Graft-versus-Host Disease (GI GVHD). The EMEA agreed that should the new ... significant unmet medical need of acute GI GVHD. We anticipate patient enrollment to ... there are no approved products to treat GI GVHD. The first trial was a 60-patient Phase ...

Article: DOR BioPharma receives Orphan Drug designation from Australian ...
Transplant News;  December 1, 2008 ;     600 words ... ... Australia has designated orBec as an Orphan Drug for the treatment of patients with gastrointestinal Graft versus Host Disease (GI GvHD) following allogeneic hematopoietic cell transplantation. The Australia Orphan Drug Program, launched in 1998 by TGA, is ...

Article: Lev Pharmaceuticals Receives Fast Track Designation ...
PR Newswire;  December 19, 2005 ;     700+ words ... ... 19 /PRNewswire-FirstCall/ -- Lev Pharmaceuticals, Inc. (BULLETIN BOARD: LEVP ... D., Chief Executive Officer of Lev Pharmaceuticals. "This is the only clinical trial ... BLA) for marketing approval. Lev Pharmaceuticals initiated its Phase III trial of ...

Article: Lev Pharmaceuticals Initiates Prophylaxis Treatment ...
PR Newswire;  November 1, 2005 ;     700+ words ... ... 1 /PRNewswire-FirstCall/ -- Lev Pharmaceuticals, Inc. (BULLETIN BOARD: LEVP ... angioedema in the United States." Lev Pharmaceuticals initiated its Phase III trial of ... D., Chief Executive Officer of Lev Pharmaceuticals. "The initiation of this prophylactic ...

Article: Lev Pharmaceuticals to Present at the Rodman & ...
PR Newswire;  November 2, 2005 ;     700+ words ... ... 2 /PRNewswire-FirstCall/ -- Lev Pharmaceuticals, Inc. (BULLETIN BOARD: LEVP ... D., Chief Executive Officer of Lev Pharmaceuticals, Inc. is scheduled to present ... of inflammatory attacks. About Lev Pharmaceuticals, Inc. Lev Pharmaceuticals, Inc ...